A Growing List: Experts Warn of Drugs with Questionable Benefits
For the 13th consecutive year, the independent journal Prescribe, run by a non-profit group of healthcare professionals, has released its updated list of drugs to approach with caution. This year’s list identifies 106 active ingredients, raising concerns about potential risks outweighing benefits in many cases.
While 88 of these ingredients are still available in France despite being banned in certain European countries, the journal’s findings highlight a growing debate about drug safety and efficacy. Many experts are calling for a more critical evaluation of medications and a shift towards prioritizing patient well-being over simply prescribing the latest pharmaceuticals.
One example highlighted by Prescribe is Floroglucinolo, sold under the brand name Spasfon. Marketed to treat a range of issues from intestinal discomfort to menstrual cramps, its effectiveness remains unproven and potential side effects include serious allergic reactions and even Lyell’s syndrome, a severe skin condition.
"While marketed as a solution for these ailments, its effectiveness is not supported by solid clinical tests and may not exceed that of a placebo," says Prescribe.
The journal also criticizes the overuse of certain cough syrups. Oxomemazine (Toplexil) presents a concerning side effects profile, and Ambroxolo (Muxol) has shown potential for triggering serious allergic and skin reactions. Even dextromethorphan, often considered a safe cough suppressant, is acknowledged by Prescribe to have limitations.
Prescribe‘s message is clear: when it comes to your health, don’t blindly accept all medications. Open, honest communication with your doctor about potential benefits and risks is crucial, allowing for a more personalized and informed approach to treatment.
The journal emphasizes that the pharmaceutical landscape is constantly changing. In 2025, a new set of guidelines and recommendations will further highlight this evolving landscape.
Several drugs, like Fenfluramine, will remain on the list due to an unfavorable risk-benefit ratio despite recent research exploring its potential in treating Lennox syndrome.
The Need for Vigilance:
The Prescribe list extends beyond individual drugs, encompassing various therapeutic categories. Oncology, transplants, hematology, cardiology, dermatology, diabetology, pain management, and even mental health – all areas face scrutiny regarding certain medications. Prescribe calls for continued vigilance and a commitment to prioritizing patient safety through open dialogue, critical evaluation of available options, and a proactive approach to healthcare.
Doctors, patients, and researchers must work together to ensure that medication choices align with the highest standards of safety and efficacy.